Effect | Decrease |
Trial Design | Double blind |
Trial Length | 1-6 months |
Number of Subjects | 202 |
Sex | Both Genders |
Age Range | 45-64 |
Supplementation of 450mg valerian root (0.8% valerenic acid) for 8 weeks as a sleep aid in persons undergoing cancer therapies noted that self-reported fatigue was less in the valerian group relative to placebo, and there appears to be no significant benefits to sleep quality (assessed by PSQI) despite improvement to both sleep latency and overall impairments to sleep (reduced from 84% to 60%)